Jeremy M. Levin - Feb 23, 2023 Form 4 Insider Report for Ovid Therapeutics Inc. (OVID)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	OVID	Stock Option (Right to Buy)	Award	$0	+600K		$0.00	600K	Feb 23, 2023	Common Stock	600K	$2.50	Direct	F1

Showing 1 to 1 of 1 entries

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	25% of the shares subject to the Stock Option will vest and become exercisable on February 23, 2024 and the remaining shares will vest in 36 equal monthly installments thereafter subject to the Reporting Person's continued services through such date.